If you’re pregnant and taking Suboxone, staying on your prescribed dose is usually safer than stopping. SAMHSA considers buprenorphine safe during pregnancy, while withdrawal often leads to return to use. A 2024 cohort study found neonatal abstinence syndrome in 37.4% of Suboxone-exposed babies versus 55.8% with buprenorphine alone, with no rise in birth defects or preterm birth. Your OB and addiction specialist should guide any change. Here’s what the evidence means for your pregnancy.
Key Takeaways
- Continuing buprenorphine/naloxone (Suboxone) during pregnancy is safer than stopping, because withdrawal often leads to return to opioid use.
- A 2024 cohort study found NAS in 37.4% of Suboxone-exposed infants versus 55.8% with buprenorphine alone.
- Compared with buprenorphine alone, Suboxone showed no increased risk of major congenital malformations, low birth weight, or preterm birth.
- SAMHSA considers both Suboxone and methadone safe in pregnancy, and switching a stable regimen mid-pregnancy is not recommended.
- OB and addiction specialists should guide any start, stop, or switch to avoid precipitated withdrawal and to plan newborn care.
Why is Suboxone considered during pregnancy
Suboxone is considered during pregnancy because continuing medication for opioid use disorder (MOUD) is one of the most protective steps you can take for yourself and your baby, and SAMHSA states that buprenorphine, its main ingredient, can be used safely during pregnancy. Clinicians recommend MOUD over medically supervised withdrawal because withdrawal often leads to return to use and can worsen outcomes. Steady treatment helps you avoid cycles of opioid use and withdrawal.
Buprenorphine/naloxone (Suboxone) combines buprenorphine, which treats opioid use disorder (OUD), with naloxone, which deters injection misuse. Newer research is reassuring. A 2023 meta-analysis found no increase in adverse neonatal outcomes compared with methadone or buprenorphine alone. Still, you’ll want to individualize your choice with your pregnancy-care and addiction-treatment teams, who know your full history.
What the medical evidence says about buprenorphine in pregnancy
Recent evidence shows that buprenorphine/naloxone (Suboxone) during pregnancy is linked to lower rates of neonatal abstinence syndrome (NAS) than buprenorphine alone, with no difference in major birth outcomes. A large 2024 cohort study comparing the two found:
- NAS affected 37.4% of Suboxone-exposed infants versus 55.8% with buprenorphine alone (weighted RR 0.77; 95% CI 0.70, 0.84).
- NICU admission was 30.6% versus 34.9%.
- Major congenital malformations, low birth weight, and preterm birth didn’t differ between groups.
- Respiratory symptoms and cesarean delivery rates were also similar.
A 2023 meta-analysis adds reassurance. It found no increase in adverse neonatal outcomes with Suboxone compared with methadone or buprenorphine alone. Still, these findings describe groups, not your individual pregnancy. Your newborn may still experience withdrawal, and that doesn’t mean treatment failed. Review your options and newborn monitoring plans with your pregnancy-care and addiction-treatment teams.
Why abruptly stopping opioids can be more dangerous than continuing MAT
Stopping opioids during pregnancy, even through medically supervised withdrawal, carries greater risks than continuing medication for opioid use disorder (MOUD) because withdrawal is associated with high rates of return to substance use, which can worsen outcomes for you and your baby. It might seem like the safest choice for your baby, but continuing treatment helps you avoid repeated cycles of opioid use and withdrawal. SAMHSA states buprenorphine and methadone can be used safely during pregnancy, and pregnancy alone isn’t a reason to change a stable regimen.
Don’t stop or switch your medication without clinical guidance. Abrupt discontinuation can destabilize your treatment, and some medication changes can trigger precipitated withdrawal. Work with your pregnancy-care and addiction-treatment teams to adjust your plan. Medication plus evidence-based behavioral support can strengthen recovery.
How Suboxone compares to methadone for pregnant women
SAMHSA considers both Suboxone (buprenorphine/naloxone) and methadone safe to use during pregnancy.
| Factor | Suboxone | Methadone |
|---|---|---|
| SAMHSA safety view | Safe in pregnancy | Safe in pregnancy |
| Adverse neonatal outcomes | No increase (2023 meta-analysis) | Comparison reference |
| NAS treatment | Some evidence of lower rates | Some evidence of higher rates |
| Switching mid-pregnancy | Stay on stable regimen | Don’t switch to buprenorphine |
If you’re already stable on methadone, pregnancy alone isn’t a reason to switch, because transitions carry risks. If you’re starting treatment, you and your care teams can weigh the evidence against your history, access, and personal needs. Remember, NAS can still occur with either medication. Neither choice reflects failure. Both protect you and your baby.
What NAS looks like with buprenorphine (typically milder)
Babies exposed to buprenorphine before birth may show signs of neonatal abstinence syndrome (NAS), also called neonatal opioid withdrawal syndrome (NOWS), in the days after delivery. NAS is a possible consequence of prescribed treatment, not a sign that your treatment failed.
The evidence shows:
- In a 2024 study, 37.4% of buprenorphine/naloxone-exposed infants developed NAS, versus 55.8% with buprenorphine alone.
- NICU admission was 30.6% versus 34.9%, respectively.
- A 2023 meta-analysis linked buprenorphine/naloxone to lower NAS treatment rates than methadone in some studies.
- Earlier adjusted analyses weren’t statistically significant, so your baby’s individual outcomes may differ.
Before delivery, ask your maternity and pediatric teams how they’ll monitor and treat your newborn, so you can plan with confidence.
Why this decision must involve an OB and addiction specialist
Both your obstetrician and your addiction specialist need to guide any decision to start, stop, or switch Suboxone, because every medication change during pregnancy carries its own risks. Poorly timed switches can trigger precipitated withdrawal, and abrupt discontinuation can destabilize your recovery. SAMHSA advises against switching from methadone to buprenorphine during pregnancy, and pregnancy alone isn’t a reason to change a stable regimen. Your team weighs the evidence alongside your history, dose, and health to decide whether buprenorphine/naloxone or buprenorphine alone fits you best.
They’ll also plan labor pain relief, since your maintenance dose may not cover delivery pain, and they’ll avoid agonist-antagonist medicines like nalbuphine that can precipitate withdrawal. Together, you’ll coordinate your newborn’s monitoring and postpartum follow-up so your treatment continues after delivery without dangerous gaps.
How Pathways Recovery provides MAT support for pregnant women
Pathways Recovery provides MAT support for pregnant women by keeping your treatment stable and coordinating it with your prenatal care. We won’t ask you to stop a working regimen because you’re pregnant. We help you and your clinicians weigh the evidence and your circumstances.
- Continuity of medication: You’ll stay on buprenorphine or buprenorphine/naloxone unless a qualified clinician directs a change.
- Team coordination: We’ll work with your OB and addiction specialist on dosing and follow-up.
- Behavioral support: You’ll receive evidence-based counseling alongside medication.
- Delivery and postpartum planning: We’ll help you prepare for labor pain control, newborn monitoring, and ongoing care after birth.
NAS/NOWS can happen with prescribed treatment, and it doesn’t mean you’ve failed. Our goal is protecting your recovery and your baby’s health.
Keep Your Opioid Treatment on Track
If you take Suboxone during pregnancy, staying connected with your addiction and prenatal care teams is important before delivery and after birth. Pathways Recovery provides medication-assisted treatment for opioid use disorder using Suboxone alongside ongoing clinical care.
Call (916) 735-8377 to discuss opioid treatment and your next step.
Frequently Asked Questions
Can I Breastfeed While Taking Suboxone After My Baby Is Born?
Breastfeeding may be appropriate for some people who are stable on buprenorphine or buprenorphine/naloxone and are not using illicit opioids or other substances that could harm the infant. Only small amounts of buprenorphine and naloxone enter breast milk, and major guidelines generally support breastfeeding when the mother’s treatment and health status make it appropriate. Discuss your feeding plan with your obstetric and pediatric care teams before delivery.
Will I Receive Enough Pain Relief During Labor While on Suboxone?
Yes. People taking Suboxone can receive effective pain relief during labor and delivery. Buprenorphine may be continued during labor, while additional pain-management strategies can be used when needed. Your maternity team should know that you are taking Suboxone so they can plan appropriately. Regional anesthesia, non-opioid medications, and additional opioid analgesia may be considered depending on your situation.
Which Pain Medications Should Be Avoided During Delivery if I Take Suboxone?
Certain opioid agonist-antagonist medications, including butorphanol, nalbuphine, and pentazocine, can interfere with opioid maintenance treatment and may precipitate withdrawal. Your maternity team should know that you are taking buprenorphine before labor so they can choose an appropriate pain-management plan. Do not stop Suboxone on your own to make pain medication easier to use.
Should I Change My Suboxone Dose as My Pregnancy Progresses?
Do not change your Suboxone dose without guidance from your prescribing clinician. Some people need dose adjustments during pregnancy if cravings or withdrawal symptoms change, while others remain stable on their existing dose. Your addiction treatment and prenatal care teams can monitor your symptoms and determine whether an adjustment is appropriate. Maintaining stable treatment is generally safer than stopping or repeatedly changing medication without medical guidance.
What Happens to My Suboxone Treatment After I Give Birth?
Suboxone treatment can continue after delivery, and postpartum care should be planned before the baby arrives. Your provider may reassess your dose, cravings, recovery needs, mental health, and breastfeeding plans after delivery. Do not abruptly stop or reduce Suboxone without medical guidance because withdrawal and relapse can create significant risks. Continued medication treatment, counseling, and recovery support can help maintain stability during the postpartum period.